Evidence map›Paper›PMID 35135442›Full record

ArticlePediatric hematology and oncology2022

Robust immune responses to SARS-CoV-2 in a pediatric patient with B-Cell ALL receiving tisagenlecleucel.

Oren M Gordon, Madeline Terpilowski, Robin Dulman, Michael D Keller, Peter D Burbelo, Jeffrey I Cohen, Catherine M Bollard, Hema Dave

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric hematology and oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Oren M GordonDepartment of Pediatrics, Children's National Hospital, Washington, DC, USA.
Madeline TerpilowskiCenter for Cancer and Immunology Research, Children's Research Institute, Children's National Hospital, Washington, DC, USA.
Robin DulmanPediatric Specialists of Virginia, Department of Pediatric Hematology and Oncology, Fairfax, VA, USA.
Michael D KellerDepartment of Pediatrics, Children's National Hospital, Washington, DC, USA.
Peter D BurbeloNational Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA.
Jeffrey I CohenLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Catherine M BollardDepartment of Pediatrics, Children's National Hospital, Washington, DC, USA.ORCID 0000-0001-5140-9090
Hema DaveDepartment of Pediatrics, Children's National Hospital, Washington, DC, USA.ORCID 0000-0003-4558-6933
Children's National · USNational Institutes of Health · USVirginia Cancer Specialists · US

Funding

Serologic studies of persons with COVID-19 infectionZIAAI001258 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI COHEN, JEFFREY · 2020 to 2025
$411k
Intramural NIH HHS ZIA AI001258
6 · The paper itself

Abstract

Recipients of anti-CD19 targeted therapies such as chimeric antigen receptor (CAR)-T cell are considered at high risk for complicated Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection due to prolonged B cell aplasia and immunosuppression. These patients represent a unique cohort and so far, immune responses to SARS-CoV-2 have not been well characterized in this setting. We report a pediatric patient with B-cell acute lymphoblastic leukemia (B-ALL) who had asymptomatic SARS-CoV-2 infection while receiving blinatumomab, followed by lymphodepletion (LD) and tisagenlecleucel, a CD19 targeting CAR-T therapy. The patient had a complete response to tisagenlecleucel, did not develop cytokine release syndrome, or worsening of SARS-CoV-2 during therapy. The patient had evidence of ongoing persistence of IgG antibody responses to spike and nucleocapsid after LD followed by tisagenlecleucel despite the B-cell aplasia. Further we were able to detect SARS-CoV-2 specific T-cells recognizing multiple viral structural proteins for several months following CAR-T. The T-cell response was polyfunctional and predominantly CD4 restricted. This data has important implications for the understanding of SARS-CoV-2 immunity in patients with impaired immune systems and the potential application of SARS-CoV-2-specific T-cell therapeutics to treat patients with blood cancers who receive B cell depleting therapy.

Indexed as

COVID-19Receptors, Chimeric AntigenAntigens, CD19ChildHumansImmunityReceptors, Antigen, T-CellSARS-CoV-2Antigens, CD19Receptors, Antigen, T-CellReceptors, Chimeric AntigentisagenlecleucelCD19 directed therapychimeric antigen receptorSARS-CoV-2T-cell responsetisagenlecleucel

Identifiers

PMID35135442
PMCPMC11524425
OpenAlexW4210839002

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.